T细胞在胃癌免疫联合化疗预后中的研究进展  

Research Progress of T Cells in Prognosis of Gastric Cancer by Immunotherapy Combined with Chemotherapy

作　　者：王雅静 刘彩霞[1] 

机构地区：[1]内蒙古医科大学附属医院肿瘤内科,内蒙古 呼和浩特

出　　处：《临床医学进展》2024年第5期1859-1864,共6页Advances in Clinical Medicine

摘　　要：胃癌是我国最常见的恶性肿瘤之一。免疫结合化疗的治疗方法在对晚期胃癌的临床研究中取得了更好的疗效,但仍有很多患者无法从中获益,存在免疫耐受现象及发生严重的免疫相关不良反应。如何在晚期胃癌患者中,选择免疫联合化疗的优势人群是临床上亟需解决的问题。T淋巴细胞是目前胃癌预后的潜在预测标志物。其与胃癌的发生、发展及预后关系目前已成为研究热点。本文就免疫联合化疗下胃癌的预后与T淋巴细胞亚群关系的研究进展进行综述。Stomach cancer is one of the most common malignant tumors in our country. Immunotherapy combined with chemotherapy has achieved better efficacy in clinical studies on advanced gastric cancer, but there are still many patients who cannot benefit from it, and there are immune tolerance phenomena and serious immune-related adverse reactions. How to select the dominant group of immune combined chemotherapy in advanced gastric cancer patients is an urgent problem to be solved clinically. T lymphocytes are potential prognostic markers of gastric cancer. Its relationship with the occurrence, development and prognosis of gastric cancer has become a research hotspot. In this review, the relationship between the prognosis of gastric cancer and T lymphocyte subsets under immunotherapy combined with chemotherapy was reviewed.

关 键 词：胃癌 T细胞 免疫联合化疗 

分 类 号：R73[医药卫生—肿瘤]